Darwin Global Management, Ltd.

ST. HELIER, Y9 · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$3.99B2026 Q3
Positions5
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

Darwin Global Management, Ltd. reported 5 positions worth $3.99B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: RVMD (54.7%). Biggest move: exit INSM ($673.6M).

5 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 RVMDRevolution Medicines$2.18B54.66%10,629,822——-16.1%
▸ 2 GMABGenmab A/S$638.6M16.00%17,899,876———
▸ 3 BLTEBelite Bio$526.0M13.18%3,097,132——-3.2%
▸ 4 ABVXAbivax S.A.$398.2M9.98%4,021,583———
▸ 5 ROIVRoivant Sciences$246.7M6.18%6,747,300——+8.1%

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Darwin Global Management, Ltd. hold as of Q3 2026?

Darwin Global Management, Ltd. reported 5 positions worth $3.99B in its Q3 2026 13F filing. Largest positions: RVMD (54.7%), GMAB (16.0%), BLTE (13.2%), ABVX (10.0%) and ROIV (6.2%).

What did Darwin Global Management, Ltd. buy in Q3 2026?

New positions: GMAB. Added to: ABVX and BLTE.

What did Darwin Global Management, Ltd. sell in Q3 2026?

Sold out entirely: INSM.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.